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Abstract 
Introduction: This case was to describe a patient presented a 6 h length of apnea 
associated with low cholinesterase activity.
Case description: A 32 years old female patient (body weight 50 kg, height 160 cm) 
was admitted to the hospital for laparoscopy combined with hysteroscopy explora-
tion. The preoperative interrogation revealed no significant personal or family history 
of adverse reaction to anesthetics. The patient was healthy, with no chronic or systemic 
disease. ASA classification is I. We performed a general anesthesia with intubation to 
the patient. Succinylcholine 100 mg was administered in anesthesia induction. After 
intubation, cisatracurium 3 mg and 3% sevoflurane were used for anesthesia mainte-
nance. The patient had been mostly unresponsive to external stimuli for 10 min since 
the end of the operation. Six hours after operation, the patient had totally recovered 
from paralysis and tracheal tube was extubated. The plasma cholinesterase test 
showed 291 U/L, significantly below normal (4650–10,440 U/L). Three days after opera-
tion, the patient was discharged from hospital with no special discomfort.
Discussion and evaluation: Reduced plasma cholinesterase activity may occur as 
a result of inherited, acquired defects or iatrogenic causes. If the acquired defects are 
excluded, low BChE activity is usually considered to be caused by mutations in butyryl-
cholinesterase gene (BCHE). 80% of the patients experiencing prolonged neuromus-
cular blockade following mivacurium have butyrylcholinesteraseen enzyme (BChE) 
deficiency of genetic origin. The novel mutation of BChE gene is usually associated 
with the ethnic of the patients. There is no specific treatment for butyrylcholinesterase 
deficiency and the mainstream is to maintain ventilatory support until succinlcholine 
is metabolized out of the myoneural junction and neuromuscular function recovers. 
Transfusion of fresh frozen plasma is also viable.
Conclusions: Plasma cholinesterase deficiency is a genetic or acquired condition. 
The most obvious feature of this genetic variants is prolonged recovery from paralysis 
in which administrated with succinylcholine or mivacurium. Once this is suspected, 
a laboratory test is important. There is no specific treatment for plasma cholinester-
ase deficiency. The best and safest way is to let the patient recover spontaneously. 
Mechanical ventilation support is important.
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Case report
Cholinesterase is produced by liver and released into plasma. It is involved in the hydrol-
ysis of ester bonds in muscle relaxants like succinylcholine and several other drugs. It is 
reported in the case prolonged recovery from paralysis caused by cholinesterase defi-
ciency in a healthy young woman who was not diagnosed so preoperatively.
A 32-year-old female patient (weight 50 kg, height 160 cm), ASA I, was admitted to 
our hospital for laparoscopy combined with hysteroscopy exploration. The preoperative 
evaluation revealed no significant personal or family history for adverse reaction to anes-
thetics. Her preoperative tests were normal, including blood routine examination, liver 
and kidney function, ECG and chest radiograph. A general anesthesia was scheduled 
for this patient. Midazolam 2  mg, fentanyl 0.2  mg, propofol 100  mg and succinylcho-
line 100 mg were administered for anesthesia induction. After intubation, cisatracurium 
3 mg and 3% sevoflurane were used for anesthesia maintenance. The operation finished 
successfully within 45 min. The vital signs had been stable during the operation.
The patient was mostly unresponsive to external stimuli for 10 min since the end of the 
operation. So we gave her neostigmine (1 mg) and atropine (0.5 mg) to reverse the neu-
romuscular blockade. As our hospital did not have a peripheral nerve stimulator, it was 
hard to accurately assess the extent of neuromuscular blockade. We had to keep stimu-
lating the patient and observed the reaction. But the patient was still unconscious 30 min 
after the operation. The artery blood gas analysis showed slight respiratory acidosis (pH 
7.308, PCO2: 48.8 mmHg, PO2: 480 mmHg, BE −2 mmol/L, HCO−3 : 24.6 mmol/L, SPO2 
100%, Na+: 140 mmol/L, K+: 3.8 mmol/L, iCa2+: 1.13 mmol/L, Hct: 0.34, Hb: 118 g/L). 
We suspected the neuromuscular blockade might not be reversed.
One hour and 25  minutes after operation, the patient coughed when endotracheal 
tube suction. Two hours and fifteen minutes after operation, the tidal volume of the 
patient still could not reach the standard. Thus, we delivered her into ICU with tracheal 
tube. Before delivery, the venous blood samples were sent to test plasma cholinester-
ase level. Six hours after operation, the patient had totally recovered from paralysis and 
tracheal tube was extubated. The plasma cholinesterase test showed 291 U/L, far below 
the standard (4650–10,440 U/L). Three days after operation, the patient was discharged 
home without special discomfort.
Discussion
When prolonged neuromuscular blockade happens, a systematic review was necessary 
to perform. First of all, which kind of neuromuscular relaxant was used? Non-depolar-
izing or depolarizing, the total dosage, the time of use. In this case, we had used suc-
cinylcholine as muscle relaxant during induction, followed with cisatracurium 3  mg. 
Succinylcholine is commonly used in the surgical rapid-sequence intubation because 
of its quick effect and short duration of action (Leadingbam 2007). The onset of mus-
cle relaxant after intravenous injection occurs in about 1  min. After a single intubat-
ing dose, a complete recovery normally occurs in about 10–12 min. It is hydrolyzed by 
plasma cholinesterase (Dell 1996). Reduced plasma cholinesterase activity may occur 
as a result of inherited, acquired defects or iatrogenic causes (Soliday 2010). Low BChE 
activity is associated with hepatic and renal diseases. For example, oral contraceptives 
may decrease the level of BChE, and metoclopramide may lead to low BChE activity. If 
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the acquired defects are excluded, low BChE activity is usually considered to be caused 
by mutations in butyrylcholineesterase gene (BCHE) (Wichmann et al. 2016). Eight per-
centage of the patients experiencing prolonged neuromuscular blockade following miva-
curium have butyrylcholineesterase enzyme (BChE) deficiency of genetic origin (Ok 
et al. 2013). BChE deficiency is an autosomal recessive trait. The most important vari-
ants are the atypical (A-variants), the Kalow (K-variants), the fluoride (F-variants) and 
the silent variants. In the White population, the A- and K-variants are the most com-
mon. There was little information on genetic variants of BChE in Chinese population 
(Lockridge 2015). The novel mutation of BChE gene is usually associated with the ethnic 
of the patients. In this case, the patient was born in Sichuan, China, Han ethnic group. 
We also measured the plasma cholinesterase of the patient’s sister. It showed that her 
plasma cholinesterase was significantly below normal. It suggests that the family carries 
a genetic variant of BChE.
There is no specific treatment for butyrylcholineesterase deficiency and the main-
stream is to maintain ventilatory support until succinylcholine is metabolized out of the 
myoneural junction and neuromuscular function recovers. Transfusion of fresh frozen 
plasma is also viable.
Once a patient was suspected with plasma cholinesterase deficiency, the following 
measures could be very important: first of all, mechanical ventilation with sedation is 
necessary until succinylcholine is completely metabolized; secondly, succinylcholine 
must be avoided; thirdly, test of plasma cholinesterase level of the patient and his/her 
family members is need; fourthly, marking the patient as plasma cholinesterase defi-
ciency patient; In the end, reviewing the family history of plasma cholinesterase is 
important.
The limitation of this case is we did not use the neuromuscular stimulator to measure 
the neuromuscular blockade because our hospital did not have it. However, it is very 
important to use a neuromuscular stimulator when muscle relaxant was used. Lack of 
neuromuscular monitoring may increase the risk of distressing awareness, which may 
lead to post traumatic stress disorder (PTSD) (Thomsen et al. 2015). The patient should 
be sufficiently sedated until recovery, if the hospital did not have a neuromuscular 
stimulator.
Summary
Plasma cholinesterase deficiency is a genetic or acquired condition.
The most obvious feature of this disease is prolonged recovery from paralysis in which 
administrated with succinylcholine or mivacurium. Once this disease is suspected, a lab-
oratory test is important. Furthermore, the patient’s family should be tested for BChE 
deficiency. There is no specific treatment for plasma cholinesterase deficiency. The best 
and safest way is to let the patient recover spontaneously. Mechanical ventilation sup-
port with sufficiently sedated is important.
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